Measurement of β2M is part of the baseline work‐up in patients with multiple myeloma and follicular lymphoma, although the role of β2M as an adverse prognostic factor in lymphoproliferative diseases is not fully understood.8, 9, 10, 11. This evidence concerns the gene B2M and follicular lymphoma.